Ranibizumab for the treatment of degenerative ocular conditions

Triantafylla, Magdalini; Massa, Horace; Dardabounis, Doukas; Gatzioufas, Zisis; Kozobolis, Vassilios; Ioannakis, Konstantinos; Perente, İrfan; Panos, Georgios D

doi:10.2147/opth.s40350

Cited by 12 publications

(6 citation statements)

References 134 publications

(141 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 More recently, however, several landmark clinical trials have established anti-VEGF treatment as the first-line therapy in many patients with DMO. 11,12 Nevertheless, many patients respond poorly to anti-VEGF treatment with transient or incomplete resolution of fluid. 4,13 According to a recent DRCR.net analysis, approximately 40% of eyes had persistent DMO after 24 weeks of monthly ranibizumab injections.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review

et al. 2018

View full text Add to dashboard Cite

Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN®. The results of the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) studies are also presented together with the results of real-world studies to support the clinical use of ILUVIEN® in achieving efficient resolution of DMO and improving vision and macular anatomy in this challenging group of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Retinopathy of prematurity is the most obvious indication in which to evaluate the potential benefit of IDO1 inhibition given that this is the disease that the OIR protocol most closely models. Additionally, however, a number of other retinopathies might also benefit from IDO1 inhibitor treatment as indicated by the effectiveness of the anti-VEGF-A antibody Fab, ranibizumab, for treating diseases such as wet macular degeneration and diabetic retinopathy (Triantafylla et al, 2014). Despite the effectiveness of anti-VEGF-A antibody therapy for treating various ocular diseases, there are also notable drawbacks to its use.…”

Section: Discussionmentioning

confidence: 99%

IDO1 is an Integral Mediator of Inflammatory Neovascularization

et al. 2016

View full text Add to dashboard Cite

The immune tolerogenic effects of IDO1 (indoleamine 2,3-dioxygenase 1) have been well documented and genetic studies in mice have clearly established the significance of IDO1 in tumor promotion. Dichotomously, the primary inducer of IDO1, the inflammatory cytokine IFNγ (interferon-γ), is a key mediator of immune-based tumor suppression. One means by which IFNγ can exert an anti-cancer effect is by decreasing tumor neovascularization. We speculated that IDO1 might contribute to cancer promotion by countering this anti-neovascular effect of IFNγ, possibly through IDO1-potentiated elevation of the pro-tumorigenic inflammatory cytokine IL6 (interleukin-6). In this study, we investigated how genetic loss of IDO1 affects neovascularization in mouse models of oxygen-induced retinopathy and lung metastasis. Neovascularization in both models was significantly reduced in mice lacking IDO1, was similarly reduced with loss of IL6, and was restored in both cases by concomitant loss of IFNγ. Likewise, the lack of IDO1 or IL6 resulted in reduced metastatic tumor burden and increased survival, which the concomitant loss of IFNγ abrogated. This insight into IDO1's involvement in pro-tumorigenic inflammatory neovascularization may have important ramifications for IDO1 inhibitor development, not only in cancer where clinical trials are currently ongoing, but in other disease indications associated with neovascularization as well.

show abstract

“…PlGF binds to VEGFR1 and collaborates with VEGF-A in promoting angiogenesis and vascular permeability. The monoclonal antibodies ranibizumab [13,14] and bevacizumab [15,16] target multiple VEGF-A isoforms [1], whereas aflibercept, unlike the monoclonal antibodies, is a soluble decoy receptor fusion protein that inhibits PlGF in addition to all isoforms of VEGF-A and VEGF-B [17,18,19]. …”

Section: Introductionmentioning

confidence: 99%

Aflibercept as First-Line Therapy in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Prospective Case Series Analysis in Real-Life Clinical Practice

et al. 2016

View full text Add to dashboard Cite

Purpose: To assess the 13-month effectiveness and safety of aflibercept in naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting. Methods: Thirty-two treatment-naïve patients with nvAMD participated in a prospective two-center study. Patients received intravitreal injections of aflibercept (Eylea®), a loading dose of three monthly injections (2 mg/0.05 ml) every 4 weeks for the first 3 months, followed by intravitreal injections every 2 months. Results: At 3 and 13 months, the mean best-corrected visual acuity improved significantly as compared with baseline (logMAR 0.53 ± 0.30 and 0.55 ± 0.32 vs. 0.30 ± 0.24, respectively, p < 0.001). At 3 and 13 months, 46.8% of patients (15/32) gained ≥15 ETDRS letters. The mean decrease in central macular thickness was also significant at 3 months (252 ± 35 µm) and at 13 months (249 ± 38 µm) as compared with pretreatment values (383 ± 76 µm) (p < 0.01). Also, 50% resolution of pigment epithelial detachment (PED) was observed in 8 out of 9 eyes (88.9%) with PED at baseline. Intravitreal injections were well tolerated and no adverse events were recorded. Conclusion: Aflibercept was effective and safe for treating nvAMD in naïve patients in routine daily practice.

show abstract

Ranibizumab for the treatment of degenerative ocular conditions

Cited by 12 publications

References 134 publications

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review

IDO1 is an Integral Mediator of Inflammatory Neovascularization

Aflibercept as First-Line Therapy in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Prospective Case Series Analysis in Real-Life Clinical Practice

Contact Info

Product

Resources

About